{"id":59096,"date":"2026-03-09T13:38:40","date_gmt":"2026-03-09T05:38:40","guid":{"rendered":"https:\/\/flcube.com\/?p=59096"},"modified":"2026-03-09T13:40:50","modified_gmt":"2026-03-09T05:40:50","slug":"bristol-myers-squibbs-sotyktu-wins-fda-label-extension-tyk2-inhibitor-expands-to-psoriatic-arthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59096","title":{"rendered":"Bristol-Myers Squibb&#8217;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis"},"content":{"rendered":"\n<p><strong>Bristol-Myers Squibb<\/strong> (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>) announced <strong>FDA approval<\/strong> for a <strong>label extension<\/strong> of <strong>Sotyktu (deucravacitinib)<\/strong>, its <strong>selective TYK2 inhibitor<\/strong>, to include <strong>adult patients with active psoriatic arthritis (PsA)<\/strong>. The approval, following the drug&#8217;s <strong>2022 U.S. launch for plaque psoriasis<\/strong> and <strong>2023 China approval<\/strong>, leverages Sotyktu&#8217;s <strong>unique allosteric mechanism<\/strong> to address the <strong>IL-23\/IL-12\/IFN-driven inflammation<\/strong> underlying both dermatologic and rheumatologic manifestations of psoriatic disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Label extension (new indication)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sotyktu (deucravacitinib)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Selective tyrosine kinase 2 (TYK2) inhibitor (allosteric)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Active psoriatic arthritis (PsA)<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>Moderate-to-severe plaque psoriasis (U.S. Sept\u202f2022); Plaque psoriasis (China Oct\u202f2023)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-differentiation\">Mechanism of Action &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Sotyktu Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>TYK2 (tyrosine kinase 2) regulatory domain<\/td><\/tr><tr><td><strong>Binding Mode<\/strong><\/td><td><strong>Allosteric inhibition<\/strong> (unique vs. catalytic site inhibitors)<\/td><\/tr><tr><td><strong>Pathway Blockade<\/strong><\/td><td>IL-23, IL-12, and type I interferon (IFN) signaling<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td><strong>Highly selective for TYK2<\/strong> at physiologic concentrations<\/td><\/tr><tr><td><strong>JAK Sparing<\/strong><\/td><td>No inhibition of JAK1, JAK2, or JAK3<\/td><\/tr><tr><td><strong>Clinical Advantage<\/strong><\/td><td>Reduced immunosuppression risk vs. pan-JAK inhibitors; no black box warnings for thrombosis\/major adverse cardiovascular events<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Pathophysiological Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PsA Driver Cytokines:<\/strong> IL-23 and IL-12 promote Th17\/Th1 inflammation in joints and entheses<\/li>\n\n\n\n<li><strong>IFN Signature:<\/strong> Type I interferons contribute to synovitis and bone remodeling<\/li>\n\n\n\n<li><strong>TYK2 Central Role:<\/strong> Critical signaling node for all three cytokine families; selective inhibition offers efficacy with improved safety<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-impact\">Clinical &amp; Commercial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Addressable Market<\/strong><\/td><td>U.S. PsA market ~$8\u202fbillion; Sotyktu captures share from TNF inhibitors and JAK inhibitors<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Only selective TYK2 inhibitor approved; JAK-sparing safety profile supports positioning in cardiovascular-risk patients<\/td><\/tr><tr><td><strong>Oral Convenience<\/strong><\/td><td>Once-daily oral vs. injectable biologics (adalimumab, ustekinumab) and IV infusions<\/td><\/tr><tr><td><strong>Pricing Power<\/strong><\/td><td>Premium positioning justified by mechanism novelty; formulary access building on psoriasis launch<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>PsA indication filing anticipated in China 2026-2027; EU EMA submission ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Sotyktu Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>AbbVie<\/strong><\/td><td>Rinvoq (upadacitinib)<\/td><td>JAK1 selective<\/td><td>TYK2 selectivity avoids JAK-class safety concerns<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>Xeljanz (tofacitinib)<\/td><td>Pan-JAK<\/td><td>Superior safety profile; no boxed warnings<\/td><\/tr><tr><td><strong>Janssen<\/strong><\/td><td>Stelara (ustekinumab)<\/td><td>IL-12\/23 p40 inhibitor<\/td><td>Oral convenience vs. injection; TYK2 upstream of p40<\/td><\/tr><tr><td><strong>Amgen<\/strong><\/td><td>Otezla (apremilast)<\/td><td>PDE4 inhibitor<\/td><td>Superior efficacy in PsA; comparable safety<\/td><\/tr><tr><td><strong>BMS<\/strong><\/td><td><strong>Sotyktu<\/strong><\/td><td><strong>Selective TYK2 allosteric inhibitor<\/strong><\/td><td><strong>First-in-class mechanism; JAK-sparing<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-portfolio-amp-strategic-context\">Portfolio &amp; Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BMS Immunology:<\/strong> Sotyktu anchors BMS&#8217;s dermatology-rheumatology franchise alongside Orencia (abatacept) and Zeposia (ozanimod)<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> TYK2 platform being explored for lupus, inflammatory bowel disease, and other interferon-driven diseases<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project <strong>$4-5\u202fbillion peak sales<\/strong> for Sotyktu across psoriasis + PsA indications; PsA expansion accelerates trajectory<\/li>\n\n\n\n<li><strong>China Market:<\/strong> PsA diagnosis rates rising; Sotyktu well-positioned for 2026-2027 label expansion following established psoriasis presence<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch performance, ex-U.S. regulatory expansion, and competitive positioning for Sotyktu in psoriatic arthritis. Actual results may differ due to formulary negotiations, competitive dynamics with JAK inhibitors, and safety data in larger patient populations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59097,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,429,428,849,15,33],"class_list":["post-59096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-bms","tag-bristol-myers-squibb","tag-nyse-bmy","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bristol-Myers Squibb&#039;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug&#039;s 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu&#039;s unique allosteric mechanism to address the IL-23\/IL-12\/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59096\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb&#039;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug&#039;s 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu&#039;s unique allosteric mechanism to address the IL-23\/IL-12\/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59096\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T05:38:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T05:40:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bristol-Myers Squibb&#8217;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis\",\"datePublished\":\"2026-03-09T05:38:40+00:00\",\"dateModified\":\"2026-03-09T05:40:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096\"},\"wordCount\":496,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0903.webp\",\"keywords\":[\"Auto-immune\",\"BMS\",\"Bristol-Myers Squibb\",\"NYSE: BMY\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59096#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59096\",\"name\":\"Bristol-Myers Squibb's Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0903.webp\",\"datePublished\":\"2026-03-09T05:38:40+00:00\",\"dateModified\":\"2026-03-09T05:40:50+00:00\",\"description\":\"Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug's 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu's unique allosteric mechanism to address the IL-23\\\/IL-12\\\/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59096\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0903.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bristol Myers Squibb's Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59096#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb&#8217;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb's Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug's 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu's unique allosteric mechanism to address the IL-23\/IL-12\/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59096","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb's Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis","og_description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug's 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu's unique allosteric mechanism to address the IL-23\/IL-12\/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.","og_url":"https:\/\/flcube.com\/?p=59096","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-09T05:38:40+00:00","article_modified_time":"2026-03-09T05:40:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59096#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59096"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bristol-Myers Squibb&#8217;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis","datePublished":"2026-03-09T05:38:40+00:00","dateModified":"2026-03-09T05:40:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59096"},"wordCount":496,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59096#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp","keywords":["Auto-immune","BMS","Bristol-Myers Squibb","NYSE: BMY","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59096#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59096","url":"https:\/\/flcube.com\/?p=59096","name":"Bristol-Myers Squibb's Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59096#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59096#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp","datePublished":"2026-03-09T05:38:40+00:00","dateModified":"2026-03-09T05:40:50+00:00","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) announced FDA approval for a label extension of Sotyktu (deucravacitinib), its selective TYK2 inhibitor, to include adult patients with active psoriatic arthritis (PsA). The approval, following the drug's 2022 U.S. launch for plaque psoriasis and 2023 China approval, leverages Sotyktu's unique allosteric mechanism to address the IL-23\/IL-12\/IFN-driven inflammation underlying both dermatologic and rheumatologic manifestations of psoriatic disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59096#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59096"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59096#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp","width":1080,"height":608,"caption":"Bristol Myers Squibb's Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59096#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb&#8217;s Sotyktu Wins FDA Label Extension \u2013 TYK2 Inhibitor Expands to Psoriatic Arthritis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59096"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59096\/revisions"}],"predecessor-version":[{"id":59100,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59096\/revisions\/59100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59097"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}